| Nome |
# |
|
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice, file dfe4d22b-67d2-bb0a-e053-d805fe0a78d9
|
82
|
|
New insights in thyroid cancer and p53 family proteins, file dfe4d227-e5e3-bb0a-e053-d805fe0a78d9
|
57
|
|
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications, file dfe4d22e-cbfe-bb0a-e053-d805fe0a78d9
|
51
|
|
Opportunities and challenges of liquid biopsy in thyroid cancer, file dfe4d22e-7e31-bb0a-e053-d805fe0a78d9
|
48
|
|
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily, file dfe4d22e-c72d-bb0a-e053-d805fe0a78d9
|
41
|
|
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells, file dfe4d22e-6b29-bb0a-e053-d805fe0a78d9
|
40
|
|
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts, file dfe4d22e-6c5b-bb0a-e053-d805fe0a78d9
|
38
|
|
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia, file dfe4d228-ff5f-bb0a-e053-d805fe0a78d9
|
27
|
|
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients., file dfe4d22e-db5d-bb0a-e053-d805fe0a78d9
|
26
|
|
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib, file dfe4d22b-5af7-bb0a-e053-d805fe0a78d9
|
25
|
|
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report, file dfe4d22b-886e-bb0a-e053-d805fe0a78d9
|
25
|
|
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells, file dfe4d22c-1693-bb0a-e053-d805fe0a78d9
|
19
|
|
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells, file dfe4d22b-ffcd-bb0a-e053-d805fe0a78d9
|
18
|
|
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance, file dfe4d22e-6aba-bb0a-e053-d805fe0a78d9
|
17
|
|
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic, file dfe4d22e-6d48-bb0a-e053-d805fe0a78d9
|
17
|
|
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma, file dfe4d22e-b665-bb0a-e053-d805fe0a78d9
|
17
|
|
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22), file dfe4d22b-dbce-bb0a-e053-d805fe0a78d9
|
16
|
|
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib, file dfe4d22c-1ae9-bb0a-e053-d805fe0a78d9
|
16
|
|
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity, file dfe4d22c-2e89-bb0a-e053-d805fe0a78d9
|
16
|
|
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein, file dfe4d227-0251-bb0a-e053-d805fe0a78d9
|
15
|
|
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment, file dfe4d22b-8b22-bb0a-e053-d805fe0a78d9
|
15
|
|
Novel mechanisms of tumor promotion by the insulin receptor isoform a in triple-negative breast cancer cells, file dfe4d22e-68a3-bb0a-e053-d805fe0a78d9
|
15
|
|
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions, file dfe4d22e-bf74-bb0a-e053-d805fe0a78d9
|
15
|
|
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res, file dfe4d229-1692-bb0a-e053-d805fe0a78d9
|
14
|
|
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy, file dfe4d227-2b92-bb0a-e053-d805fe0a78d9
|
13
|
|
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53, file dfe4d229-d55d-bb0a-e053-d805fe0a78d9
|
13
|
|
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors, file dfe4d22b-5af8-bb0a-e053-d805fe0a78d9
|
13
|
|
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report, file dfe4d22c-1789-bb0a-e053-d805fe0a78d9
|
13
|
|
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform, file dfe4d22b-e626-bb0a-e053-d805fe0a78d9
|
11
|
|
Insulin receptor isoforms differently regulate cell proliferation and apoptosis in the ligand‐occupied and unoccupied state, file dfe4d22e-4e58-bb0a-e053-d805fe0a78d9
|
11
|
|
Diagnostic utility of the immunohistochemical expression of serin and arginine rich splicing factor 1 (Srsf1) in the differential diagnosis of adult gliomas, file dfe4d22e-5973-bb0a-e053-d805fe0a78d9
|
11
|
|
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells, file dfe4d22b-d88f-bb0a-e053-d805fe0a78d9
|
10
|
|
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release, file dfe4d226-fdee-bb0a-e053-d805fe0a78d9
|
9
|
|
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes, file dfe4d22e-e42f-bb0a-e053-d805fe0a78d9
|
8
|
|
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors, file 0478694d-d93f-4e06-9e4c-8b6109c68bcb
|
7
|
|
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer, file 2b43428e-4b42-4604-9890-d84e2cbca856
|
7
|
|
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far, file 8cc35723-4cb2-4655-b839-50fe697431f9
|
7
|
|
IRF5 promotes the proliferation of human thyroid cancer cells., file dfe4d227-8fa2-bb0a-e053-d805fe0a78d9
|
7
|
|
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation., file dfe4d22e-8d2a-bb0a-e053-d805fe0a78d9
|
7
|
|
Uncommon long-term survival in a patient with chronic myeloid leukemia, file ab6d6bef-63ae-4c05-b294-db5e16b8114b
|
6
|
|
FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series, file dfe4d22d-fc20-bb0a-e053-d805fe0a78d9
|
6
|
|
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma, file dfe4d22c-386a-bb0a-e053-d805fe0a78d9
|
5
|
|
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience, file dfe4d22e-d8e7-bb0a-e053-d805fe0a78d9
|
5
|
|
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis, file 46c7b747-96c4-4a03-92d4-3bd9fe4b5d1a
|
4
|
|
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain, file ea037a10-8667-470d-931e-c9c7b0f794bf
|
4
|
|
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy, file dfe4d227-08c8-bb0a-e053-d805fe0a78d9
|
2
|
|
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia, file dfe4d227-2f0e-bb0a-e053-d805fe0a78d9
|
2
|
|
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report, file dfe4d22c-1787-bb0a-e053-d805fe0a78d9
|
2
|
|
Comparative proteomic analysis of insulin receptor isoform A and B signaling, file c1ee7495-7a4e-438b-b245-41920b32cb5c
|
1
|
|
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase, file dfe4d226-f96a-bb0a-e053-d805fe0a78d9
|
1
|
|
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia, file dfe4d226-fe9a-bb0a-e053-d805fe0a78d9
|
1
|
|
Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor, file dfe4d227-97cf-bb0a-e053-d805fe0a78d9
|
1
|
|
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias, file dfe4d22a-1741-bb0a-e053-d805fe0a78d9
|
1
|
|
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives, file dfe4d22b-d3e2-bb0a-e053-d805fe0a78d9
|
1
|
|
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report, file dfe4d22b-dbcc-bb0a-e053-d805fe0a78d9
|
1
|
|
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop, file dfe4d22d-28ad-bb0a-e053-d805fe0a78d9
|
1
|
| Totale |
861 |